58 results
424B5
AUTL
Autolus Therapeutics plc
19 Aug 21
Prospectus supplement for primary offering
4:13pm
in concert with him are interested) carry 30% or more of the voting rights of a company; or
any person who, together with persons acting in concert with him … , is interested in shares which in the aggregate carry not less than 30% of the voting rights of a company but does not hold shares carrying more than
F-3
AUTL
Autolus Therapeutics plc
6 Aug 21
Shelf registration (foreign)
2:30pm
30% or more of the voting rights of a company; or
any person who, together with persons acting in concert with him, is interested in shares which … in the aggregate carry not less than 30% of the voting rights of a company but does not hold shares carrying more than 50% of such voting rights
S-3ASR
AUTL
Autolus Therapeutics plc
7 Feb 24
Automatic shelf registration
10:00pm
, and in which persons acting in concert with him are interested) carry 30% or more of the voting rights of a company; or
any person who, together with persons … acting in concert with him, is interested in shares which in the aggregate carry not less than 30% of the voting rights of a company but does not hold
DRS
AUTL
Autolus Therapeutics plc
23 Nov 18
Draft registration statement
12:00am
General Corporation Law relating to shareholders’ rights and protections.
You may not have the same voting rights as the holders of our ordinary … shareholders and in accordance with the provisions of the deposit agreement, will not be able to exercise voting rights attaching to the ordinary
424B4
AUTL
Autolus Therapeutics plc
11 Apr 19
Prospectus supplement with pricing info
4:10pm
voting rights as the holders of our ordinary shares and may not receive voting materials in time to be able to exercise their right to vote.
Holders … to exercise voting rights attaching to the ordinary shares evidenced by the ADSs on an individual basis. The depositary or its nominee will act
F-3
736hi5oc58583
17 Jul 19
Shelf registration (foreign)
5:15pm
F-1
t8003d1fhq7564
8 Apr 19
Registration statement (foreign)
4:34pm
424B5
vfgp0xkku0 je1t9
9 Feb 24
Prospectus supplement for primary offering
5:15pm
424B5
bdteum
24 Jul 19
Prospectus supplement for primary offering
4:20pm
8-K
EX-10.3
hxjpqx f3
8 Feb 24
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs
6:06am
424B5
8ucnz
9 Dec 22
Prospectus supplement for primary offering
5:40pm
424B5
xcwa8lv5ouq6v gi96
8 Dec 22
Prospectus supplement for primary offering
4:10pm
424B5
8mgk4555nzf zdvwfcwe
18 Sep 20
Prospectus supplement for primary offering
8:01am
6-K
EX-2
jrid1cu9
15 Mar 19
Annual Report and Accounts
5:26pm
424B5
kl8mun oj
8 Feb 21
Prospectus supplement for primary offering
5:27pm
F-6
EX-99
z6r17 pgo3bwl90
10 May 18
Registration for ADRs (foreign)
5:04pm
424B5
spobhmym amm4
11 Feb 21
Prospectus supplement for primary offering
5:16pm
6-K/A
EX-99.2
vmqizryghxtu0xob
6 Jul 23
Current report (foreign) (amended)
5:38pm